SAI Pharma CO Ltd Pharmaceutical Import Profile — Thailand (DGFT 2022–2026)

Name: SAI Pharma CO Ltd Pharmaceutical Import Records from India — 2 Products, $400.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SAI Pharma CO Ltd — Pharmaceutical Importer Profile (2026) | 2 Products, $400.0K Trade | TransData Nexus

SAI Pharma CO Ltd

Pharmaceutical Importer · Thailand · Antiviral & HIV Medications Focus · $400.0K Total Trade · DGFT Verified

SAI Pharma CO Ltd is a pharmaceutical importer based in Thailand with a total trade value of $400.0K across 2 products in 1 therapeutic categories. Based on 8 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SAI Pharma CO Ltd sources from 2 verified Indian suppliers, with Mylan Laboratories Limited accounting for 89.9% of imports.

SAI Pharma CO Ltd — Import Portfolio & Supplier Network

SAI Pharma CO Ltd import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SAI Pharma CO Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$776.6K	16	89.9%
Optimus Pharma Private Limited	$87.5K	2	10.1%

SAI Pharma CO Ltd sources from 2 verified Indian suppliers across 11 distinct formulations. The sourcing is — Mylan Laboratories Limited accounts for 89.9% of total imports, indicating a strategic single-source relationship.

What Formulations Does SAI Pharma CO Ltd Import?

Formulation	Value	Ships
Lopinavir ritonavir	$150.0K	3
Tenofovir disoproxil fumarate	$150.0K	3
Emtricitabine premix tenofovir disoproxil fumarate	$100.0K	2
Abacavir sulfate 600MG + lamivudine 300MG tablets 30s 39139 packs x 30s = 1174170	$100.0K	2
Darunavir 400 MG + ritonavir 50 MG TAB 60s packs 60s bottle2087 packs x 60s=125220	$100.0K	2
Tenofovir disoproxil fumarate 300	$50.0K	1
Lopinavir + ritonavir	$50.0K	1
Molnupiravir capsules 200 MG pharmaceutical for pharmaceutical raw material as per	$50.0K	1
Abacavir sulfate 600 MG + lamivudine	$50.0K	1
Molnupiravir capsules 200 MG	$37.5K	1
Ricovir tenofovir disoproxil fumarate300 MG tablets 30s 8000 packs x 30s 240000	$26.6K	1

SAI Pharma CO Ltd imports 11 distinct pharmaceutical formulations. Showing top 11 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ritonavir	Antiviral & HIV Medications	$300.0K	6	0.1%	6
2	Emtricitabine	Antiviral & HIV Medications	$100.0K	2	0.1%	17

SAI Pharma CO Ltd imports 2 pharmaceutical products across 1 categories into Thailand totaling $400.0K.

SAI Pharma CO Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SAI Pharma CO Ltd is a pharmaceutical importer and buyer based in Bangkok, Thailand. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a focus on antiviral and HIV medications, SAI Pharma CO Ltd plays a significant role in enhancing the availability of essential treatments within Thailand's healthcare system.

The company's headquarters are located at 402, 404 Soi Yak Soi Siripot, Sukhumvit Road, Kwaeng Khet Suanluang, Bangkok, Thailand. While specific information regarding a parent company is not publicly available, SAI Pharma CO Ltd operates independently, establishing direct relationships with international suppliers to meet the domestic demand for critical pharmaceutical products.

2Distribution Network

SAI Pharma CO Ltd's distribution network is centered in Bangkok, Thailand, serving as the primary hub for its operations. The company imports finished pharmaceutical formulations from India, which are then distributed throughout Thailand to various healthcare providers, including hospitals, clinics, and pharmacies. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic location in Bangkok facilitates efficient distribution across the country.

3Industry Role

In Thailand's pharmaceutical supply chain, SAI Pharma CO Ltd functions as a pharmaceutical importer and buyer, focusing on sourcing finished pharmaceutical formulations from international suppliers, particularly from India. By importing essential medications, the company contributes to the availability of critical treatments within Thailand's healthcare system. SAI Pharma CO Ltd's role is pivotal in ensuring that healthcare providers have access to necessary pharmaceutical products to meet patient needs.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SAI Pharma CO Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SAI Pharma CO Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value of $400,000 USD from India across 8 shipments. The company's portfolio is entirely focused on two products—Ritonavir and Emtricitabine—both integral to the treatment of HIV. This concentrated sourcing approach indicates a strategic decision to specialize in specific therapeutic areas, ensuring expertise and reliability in these products.

The shipment data reveals a stable relationship with two Indian suppliers: Mylan Laboratories Limited, accounting for 89.9% of the shipments, and Optimus Pharma Private Limited, comprising 10.1%. This dual-supplier model mitigates risks associated with single-source dependency while maintaining a focused product range. The consistent sourcing pattern suggests a well-established and dependable supply chain, essential for the uninterrupted availability of critical medications in Thailand.

2Supply Chain Resilience

SAI Pharma CO Ltd's supply chain resilience is supported by its dual-supplier strategy, involving Mylan Laboratories Limited and Optimus Pharma Private Limited. This approach reduces the risks associated with single-source dependency, ensuring a more robust supply chain capable of adapting to potential disruptions. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, allows for a more streamlined and efficient supply chain, facilitating timely deliveries to meet domestic demand.

Importing Pharmaceuticals into Thailand — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Thailand

1Regulatory Authority & Framework

In Thailand, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, manufacturing, and distribution of pharmaceutical products. The FDA operates under the Ministry of Public Health, ensuring that all pharmaceutical products meet the required safety, efficacy, and quality standards before they enter the Thai market.

The governing legislation for pharmaceutical imports is the Drugs Act B.E. 2510 (1967), which mandates that all drugs, including finished pharmaceutical products, must be registered with the FDA prior to importation. This registration process involves a comprehensive evaluation of the product's quality, safety, and efficacy. Once registered, certain products may require additional approvals, such as a Certificate of Lot Release from the Department of Medical Sciences, before distribution within Thailand. (en.fda.moph.go.th)

2Import Licensing & GMP

Import licensing is a critical component of Thailand's pharmaceutical import regulations. Importers must obtain a license from the FDA to bring pharmaceutical products into the country. This process ensures that all imported drugs comply with Thai standards and regulations. Additionally, the FDA recognizes Good Manufacturing Practice (GMP) certificates from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications are essential for suppliers aiming to export pharmaceutical products to Thailand, as they demonstrate adherence to high manufacturing standards.

SAI Pharma CO Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SAI Pharma CO Ltd's focus on antiviral and HIV medications, specifically Ritonavir and Emtricitabine, aligns with the growing demand for effective HIV treatments in Thailand. The decision to import these specific products is driven by the critical need for such medications in the Thai healthcare system, addressing both public health concerns and the requirements of healthcare providers. By concentrating on these therapeutic areas, SAI Pharma CO Ltd positions itself as a key player in the fight against HIV in Thailand.

The market demand for HIV medications in Thailand is substantial, influenced by factors such as the prevalence of HIV, government health initiatives, and the availability of treatment options. SAI Pharma CO Ltd's strategic product focus enables the company to meet this demand effectively, ensuring a steady supply of essential medications to the Thai market.

2Sourcing Profile

SAI Pharma CO Ltd's sourcing strategy is centered on importing generic formulations of Ritonavir and Emtricitabine from India. This approach allows the company to provide cost-effective treatment options without compromising on quality. India's well-established pharmaceutical industry, known for its adherence to international manufacturing standards, makes it a reliable source for these medications. By focusing on generic drugs, SAI Pharma CO Ltd can offer affordable solutions to the Thai market, addressing both economic and healthcare needs.

Seller's Guide — How to Become a Supplier to SAI Pharma CO Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with SAI Pharma CO Ltd, given the company's focused product range and established supplier relationships. Potential gaps in SAI Pharma CO Ltd's current sourcing include the need for additional suppliers to diversify the supply chain and mitigate risks associated with over-reliance on a limited number of sources. Indian exporters can explore these opportunities by offering high-quality generic formulations of Ritonavir and Emtricitabine, adhering to international manufacturing standards and obtaining the necessary certifications recognized by Thailand's FDA.

2Requirements & Qualifications

Indian exporters aiming to supply SAI Pharma CO Ltd and the broader Thai market must ensure that their products are registered with Thailand's FDA, complying with the Drugs Act B.E. 2510 (1967).

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — SAI Pharma CO Ltd

What products does SAI Pharma CO Ltd import from India?

SAI Pharma CO Ltd imports 2 pharmaceutical products across 1 categories. Top imports: Ritonavir ($300.0K), Emtricitabine ($100.0K).

Who supplies pharmaceuticals to SAI Pharma CO Ltd from India?

SAI Pharma CO Ltd sources from 2 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (89.9% of imports, $776.6K).

What is SAI Pharma CO Ltd's total pharmaceutical import value?

SAI Pharma CO Ltd's total pharmaceutical import value from India is $400.0K, based on 8 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SAI Pharma CO Ltd focus on?

SAI Pharma CO Ltd imports across 1 categories. The largest: Antiviral & HIV Medications (100.0%).

Get Full SAI Pharma CO Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.